102 related articles for article (PubMed ID: 38309282)
1. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
Mahadeo KM; Baiocchi R; Beitinjaneh A; Chaganti S; Choquet S; Dierickx D; Dinavahi R; Duan X; Gamelin L; Ghobadi A; Guzman-Becerra N; Joshi M; Mehta A; Navarro WH; Nikiforow S; O'Reilly RJ; Reshef R; Ruiz F; Spindler T; Prockop S
Lancet Oncol; 2024 Mar; 25(3):376-387. PubMed ID: 38309282
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant.
Barlev A; Zimmermann H; Guzman-Becerra N; Mehta A; Xing B; Macabeo B; Thivolet M; Brookhart MA
J Med Econ; 2024; 27(1):789-795. PubMed ID: 38727527
[TBL] [Abstract][Full Text] [Related]
3. Tabelecleucel for EBV+ PTLD following allogeneic HCT or SOT in a multicenter expanded access protocol.
Nikiforow S; Whangbo JS; Reshef R; Tsai DE; Bunin NJ; Abu-Arja RF; Mahadeo KM; Weng WK; Van Besien K; Loeb D; Nasta SD; Nemecek ER; Zhao W; Sun Y; Galderisi FC; Wahlstrom J; Mehta A; Gamelin LI; Dinavahi R; Prockop SE
Blood Adv; 2024 Apr; ():. PubMed ID: 38625984
[TBL] [Abstract][Full Text] [Related]
4. Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation.
O'Reilly RJ; Prockop S; Oved JH
Front Immunol; 2023; 14():1290059. PubMed ID: 38274824
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr Virus Monitoring after an Allogeneic Hematopoietic Stem Cell Transplant: Review of the Recent Data and Current Practices in Canada.
Ratiu C; Dufresne SF; Thiant S; Roy J
Curr Oncol; 2024 May; 31(5):2780-2795. PubMed ID: 38785492
[TBL] [Abstract][Full Text] [Related]
6. Effect of pre-emptive rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder in pediatric kidney transplant recipients: A case series from the pediatric nephrology research consortium.
Ashoor IF; Al-Akash S; Kizilbash S; Moudgil A; Puliyanda D; Ranabothu S; Shi Y; Dharnidharka V
Pediatr Transplant; 2024 May; 28(3):e14743. PubMed ID: 38566336
[TBL] [Abstract][Full Text] [Related]
7. Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study.
Walti LN; Mugglin C; Sidler D; Mombelli M; Manuel O; Hirsch HH; Khanna N; Mueller N; Berger C; Boggian K; Garzoni C; Neofytos D; van Delden C; Hirzel C;
Am J Transplant; 2021 Jul; 21(7):2532-2542. PubMed ID: 33289340
[TBL] [Abstract][Full Text] [Related]
8. Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centres.
Santarsieri A; Rudge JF; Amin I; Gelson W; Parmar J; Pettit S; Sharkey L; Uttenthal BJ; Follows GA
Br J Haematol; 2022 May; 197(3):310-319. PubMed ID: 35235680
[TBL] [Abstract][Full Text] [Related]
9. EBV-associated lymphoproliferative disease post-CAR-T cell therapy.
Zhang S; Zhou X; Zhang S; Wang N; Zhang T; Zhang D; Ao Q; Cao Y; Huang L
Front Med; 2024 Apr; 18(2):394-398. PubMed ID: 38329597
[TBL] [Abstract][Full Text] [Related]
10. T-cell therapy in the treatment of post-transplant lymphoproliferative disease.
Bollard CM; Rooney CM; Heslop HE
Nat Rev Clin Oncol; 2012 Sep; 9(9):510-9. PubMed ID: 22801669
[TBL] [Abstract][Full Text] [Related]
11. Differentiating Between Epstein-Barr Virus-positive Lymphoid Neoplasm Relapse and Post-transplant Lymphoproliferative Disorder After Sex-mismatched Hematopoietic Stem Cell Transplantation.
Kurashige R; Kurashige M; Okada Y; Higuchi K; Yuda S; Hino A; Miyamura T; Ichii M; Fukushima K; Honma K; Takeuchi M; Yokota T; Ishikawa J; Sawada A; Shibayama H; Hosen N; Morii E
Am J Surg Pathol; 2024 Apr; 48(4):395-405. PubMed ID: 38287877
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.
Shaffer DR; Rooney CM; Gottschalk S
Immunotherapy; 2010 Sep; 2(5):663-71. PubMed ID: 20874650
[TBL] [Abstract][Full Text] [Related]
13. How I treat posttransplant lymphoproliferative disorder.
Amengual JE; Pro B
Blood; 2023 Oct; 142(17):1426-1437. PubMed ID: 37540819
[TBL] [Abstract][Full Text] [Related]
14. EBV Reactivation and Lymphomagenesis: More Questions than Answers.
Ford M; Orlando E; Amengual JE
Curr Hematol Malig Rep; 2023 Dec; 18(6):226-233. PubMed ID: 37566338
[TBL] [Abstract][Full Text] [Related]
15. Tabelecleucel is effective in EBV-positive lymphoproliferative disease.
Romero D
Nat Rev Clin Oncol; 2024 Apr; 21(4):251. PubMed ID: 38374435
[No Abstract] [Full Text] [Related]
16. Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives.
Compagno F; Basso S; Panigari A; Bagnarino J; Stoppini L; Maiello A; Mina T; Zelini P; Perotti C; Baldanti F; Zecca M; Comoli P
Front Immunol; 2020; 11():567020. PubMed ID: 33042147
[TBL] [Abstract][Full Text] [Related]
17. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.
Keller MD; Hanley PJ; Chi YY; Aguayo-Hiraldo P; Dvorak CC; Verneris MR; Kohn DB; Pai SY; Dávila Saldaña BJ; Hanisch B; Quigg TC; Adams RH; Dahlberg A; Chandrakasan S; Hasan H; Malvar J; Jensen-Wachspress MA; Lazarski CA; Sani G; Idso JM; Lang H; Chansky P; McCann CD; Tanna J; Abraham AA; Webb JL; Shibli A; Keating AK; Satwani P; Muranski P; Hall E; Eckrich MJ; Shereck E; Miller H; Mamcarz E; Agarwal R; De Oliveira SN; Vander Lugt MT; Ebens CL; Aquino VM; Bednarski JJ; Chu J; Parikh S; Whangbo J; Lionakis M; Zambidis ET; Gourdine E; Bollard CM; Pulsipher MA
Nat Commun; 2024 Apr; 15(1):3258. PubMed ID: 38637498
[TBL] [Abstract][Full Text] [Related]
18. Treatment dilemma for survivors of rituximab-induced bowel perforation in the setting of post-transplant lymphoproliferative disorder.
Sullivan BJ; Kim GJ; Sara G
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567238
[TBL] [Abstract][Full Text] [Related]
19. A disease warranting attention from neurosurgeons: primary central nervous system post-transplant lymphoproliferative disorder.
Jin L; Lu D; Yan F; Han J; Wei P; Zhou Y; Wang Y; Shan Y; Zhao G
Front Neurol; 2024; 15():1392691. PubMed ID: 38813246
[TBL] [Abstract][Full Text] [Related]
20. A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma.
Tsung I; Worden FP; Fontana RJ
Oncologist; 2021 Feb; 26(2):133-138. PubMed ID: 32969143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
